

The State Health Reform in China

On the Role of Financing



刘国恩 博士


Gordon G. Liu, PhD

北京大学光华管理学院

PKU Guanghua School of Management

Email: ggliu@unc.edu

Economy and HC in China



The State Health Reform Roadmap

□ The State Leadership

- The State Council Health Reform Leadership Team, chaired by Deputy Prime Minister Li Keqiang
- The State Council Health Reform Taskforce Office, directed by Mr. Sun Zhigang (Deputy director of NDRC), joined by four core ministries (MHRSS, MF, NDRC, MOH)

□ The Advisory body

- The State Council Health Reform Advisory Commission (36 members)

The State Council Health Reform AD Commission



Task: Making The 12th 5-Y Health Plan

The Key State Health Reforms

The State Health Reform Plan


- ❑ Building social insurance for financing
- ❑ Promoting equal public health measures
- ❑ Essential drug policy intervention
- ❑ Improving community-based healthcare facility
- ❑ Reforming public hospitals and payment approach

The State〔2010〕Doc No. 58

鼓励和引导社会资本举办医疗机构，有利于增加医疗卫生资源，扩大服务供给，满足人民群众多层次、多元化的医疗服务需求；有利于建立竞争机制，提高医疗服务效率和质量，完善医疗服务体系。

各地区、各有关部门要解放思想、转变观念，充分认识鼓励和引导社会资本举办医疗机构的重要意义。

Fast Growing Insurance Coverage



Third-party payer as cost driver?



- PID: no impact
- Defensive medicine: 1%
- Aging: 7%
- Insurance: 10%
- Income: 5 ~ 25%
- Technology: > 50%



Joseph P. Newhouse

A scientific approach: Health Technology Assessment (HTA)

Medical Expenditures: Over Rx?



The State Reform Calls on PE Study

□ The State Health Reform Plan :

- “合理调整政府定价范围，改进药品定价方法，利用价格杠杆鼓励企业自主创新，促进国家基本药物的生产和使用。对新药和专利药品逐步实行上市前**药物经济性(PE)**评价制度。”

□ The MOH Essential Drug Policy :

- “目录遴选调整应当坚持科学、公正、公开、透明。建立健全循证医学、**药物经济学(PE)**评价标准和工作机制。”
- “鼓励科研机构、医药企业、社会团体等开展国家基本药物循证医学、**药物经济学(PE)**评价工作。”

□ The NDRC Pricing Directives

- 了促成科学合理的药品价格形成机制，《意见》将鼓励与支持药物创新，进行新药定价前的**药物经济学评价(PE)**。

《中国药物经济学评价指南》

China Guidelines for Pharmacoeconomic Evaluations



SANG, Guowei: The Vice Chairman of NPC

- China PE Guidelines Taskforce
 - Chief Advisor: Guowei SANG (桑国卫), China's PCC Vice Chairman
- Executive Committee
 - Chair: Gordon G LIU (刘国恩), PKU
 - Vice Chairs: Shanlian HU (胡善联), Fudan U; Jiuhong WU (吴久鸿), PLA 306 Hospital
 - Members: Jing WU (吴晶), Li YANG (杨莉), Zhaohui DONG (董朝晖), Hongchao LI (李洪超), Minghui LI (李明晖), Ning SHI (史宁), Jinghua CHANG (常精华)

Academic Response: PE Guideline

(Released on 4-9-2011)



- Guideline 1: Study Question
- Guideline 2: Study Design
- Guideline 3: Cost
- Guideline 4: Health Outcomes
- Guideline 5: Evaluation Techniques
- Guideline 6: Modeling Analysis
- Guideline 7: Variability and Uncertainty
- Guideline 8: Equity
- Guideline 9: Generalizability
- Guideline 10: Budget Impact Analysis

RDPAC: translating and releasing soon

Payment Reform Launched 2011

- MHRSS-led Effort and Guidelines
 - Inpatient: by disease or DRG
 - Outpatient: by capitation

- Possible responses by different stakeholders
 - MOH to focus EDL with more central interventions
 - NDRC to price, referencing to PE and cross-country data
 - MHRSS to demand for PE data for policy forumulary
 - Hospitals to demand for PE data
 - Manufacturers to conduct and provide PE data